Perdoceo Education (NASDAQ:PRDO) Stock

Perdoceo Education

Perdoceo Education Corp is an American for-profit education company that focuses on quality postsecondary education online to a diverse student population, along with campus-based and blended learning programs. The company's important segment include the American InterContinental University, and Colorado Technical University. These universities provide undergraduate, graduate, and doctoral degree programs focusing on business, technology, management, and social services with majority of the students enrolled in programs offered fully online. The majority of the company's revenue comes from the Colorado Technical University segment.

Amazon Ordered To Recall Over 400K Hazardous Products Sold On Its Site By US Federal Agency

Long Ideas

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

AMZN

INTC

PRDO

USAP

This Analyst With 87% Accuracy Rate Sees Around 41% Upside In Amazon.com - Here Are 5 Stock Picks For Last Week From Wall Street&#39;s Most Accurate Analysts

Alphabet.Google.Shutterstock

COIN

GOOGL

This Analyst With 86% Accuracy Rate Sees Around 16% Upside In Alphabet - Here Are 5 Stock Picks For Last Week From Wall Street&#39;s Most Accurate Analysts

C.H. Robinson Worldwide - logo

Intraday Update

Movers

ASPN

BPMC

CHRW

CVNA

ENVX

GKOS

ITRI

LNTH

LUNG

MRNA

NOVA

QCOM

TROX

C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday

Perdoceo Education Corporation - Common Stock

Perdoceo Education Corp

Guidance

KVYO

Klaviyo Sees FY25 Revenue $1.156B-$1.164B Vs $1.155B Est.

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported quarterly sales of $713.00 million which beat the analyst consensus estimate of $701.30 million by 1.67 percent. This is a 10.22 percent increase over sales of $646.88 million the same period last year.

Earnings

Earnings Beats

EXAS

Exact Sciences Q4 Sales $713.00M Beat $701.30M Estimate

Klaviyo Sees Q1 Revenue $265M-$269M Vs $264.66M Est.

Armada Hoffler Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHH#NYSE">AHH</a>) reported quarterly earnings of $0.27 per share which met the analyst consensus estimate. This is a 12.9 percent decrease over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $62.95 million which missed the analyst consensus estimate of $66.67 million by 5.58 percent. This is a 5.20 percent increase over sales of $59.84 million the same period last year.

Earnings Misses

Armada Hoffler Properties Q4 Normalized FFO per diluted share $0.27, Inline, Rental revenues $62.95M Miss $66.67M Estimate

Imax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.30 by 10 percent. This is a 58.82 percent increase over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $92.67 million which missed the analyst consensus estimate of $104.08 million by 10.96 percent. This is a 7.74 percent increase over sales of $86.02 million the same period last year.

IMAX

Imax Q4 Adj EPS $0.27 Misses $0.30 Estimate, Sales $92.67M Miss $104.08M Estimate

Mister Car Wash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCW#NYSE">MCW</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.07 by 28.57 percent. This is a 28.57 percent increase over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $251.17 million which beat the analyst consensus estimate of $248.42 million by 1.11 percent. This is a 9.14 percent increase over sales of $230.14 million the same period last year.

Mister Car Wash Q4 2024 Adj EPS $0.09 Beats $0.07 Estimate, Sales $251.17M Beat $248.42M Estimate

Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.09) by 66.67 percent. This is a 84.21 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $351.900 million which beat the analyst consensus estimate of $343.357 million by 2.49 percent. This is a 32.91 percent increase over sales of $264.758 million the same period last year.

RELY

Remitly Global Q4 2024 GAAP EPS $(0.03) Beats $(0.09) Estimate, Sales $351.900M Beat $343.357M Estimate

Bausch Health Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) reported quarterly sales of $2.56 billion which beat the analyst consensus estimate of $2.52 billion by 1.38 percent. This is a 6.27 percent increase over sales of $2.41 billion the same period last year.

Bausch Health Companies Q4 Sales $2.56B Beat $2.52B Estimate

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.35 by 2.86 percent. This is a 12.5 percent increase over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $182.35 million which beat the analyst consensus estimate of $177.96 million by 2.46 percent. This is a 11.60 percent increase over sales of $163.40 million the same period last year.

SBRA

Sabra Health Care REIT Q4 2024 FFO $0.36 Beats $0.35 Estimate, Sales $182.35M Beat $177.96M Estimate

Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.06 by 16.67 percent. This is a 22.22 percent decrease over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $270.164 million which beat the analyst consensus estimate of $257.247 million by 5.02 percent. This is a 34.00 percent increase over sales of $201.618 million the same period last year.

Klaviyo Q4 2024 Adj. EPS $0.07 Beats $0.06 Estimate, Sales $270.164M Beat $257.247M Estimate

Management

Herbalife Appoints Stephan Gratziani As Chief Executive Officer, Effective May 1

Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.53 by 73.58 percent. This is a 87.76 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $747.31 million which beat the analyst consensus estimate of $713.44 million by 4.75 percent. This is a 15.65 percent increase over sales of $646.21 million the same period last year.

BMRN

Biomarin Pharmaceutical Q4 Adj $0.92 Beats $0.53 Estimate, Sales $747.31M Beat $713.44M Estimate

Christina succeeds Brad West, who announced his retirement in 2024 after eight years as COO. West will remain with the company as Chief of Staff through June 2025 to ensure a seamless transition.

NDLS

Noodles & Company Names Joe Christina As President And COO

TFII

TFI International Q4 2024 Adj. EPS $1.19 Misses $1.60 Estimate, Sales $2.077B Miss $2.171B Estimate

Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) sees FY2025 sales of $115.000 million-$125.000 million vs $121.32 million analyst estimate.

Outset Medical Sees FY2025 Sales $115.000M-$125.000M vs $121.32M Est

MGRC

McGrath Sees FY25 Revenue $920M-$970M Up From $911M YoY; Adj EBITDA $345M-$360M.

Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.41) by 9.76 percent. This is a 37.29 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $29.47 million which beat the analyst consensus estimate of $28.47 million by 3.49 percent. This is a 3.41 percent decrease over sales of $30.51 million the same period last year.

Outset Medical Q4 Adj $(0.37) Beats $(0.41) Estimate, Sales $29.47M Beat $28.47M Estimate

Churchill Downs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) reported quarterly earnings of $0.95 per share which met the analyst consensus estimate. This is a 10.47 percent increase over earnings of $0.86 per share from the same period last year. The company reported quarterly sales of $624.20 million which beat the analyst consensus estimate of $620.22 million by 0.64 percent. This is a 11.23 percent increase over sales of $561.20 million the same period last year.

CHDN

Churchill Downs Q4 2024 GAAP EPS $0.95, Inline, Sales $624.20M Beat $620.22M Estimate

Penumbra Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) is trading higher after the company reported better-than-expected <a href="https://www.benzinga.com/pressreleases/25/02/n43796948/penumbra-inc-reports-fourth-quarter-and-full-year-2024-financial-results" target="_blank" rel="noreferrer noopener">fourth-quarter earnings</a>.
The medical device company reported:
<ul>
<li>Adjusted EPS of 97 cents, up from 76 cents a year ago, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 90 cents</a>.</li>
<li>Sales of $315.52 million, up 10.8% year over year and beating the consensus of $311.55 million.</li>
<li>Global thrombectomy product Q4 sales grew to $220.1 million, an increase of 15.4% in reported and constant currency</li>
<li>U.S. thrombectomy product sales increased by 27.3%.</li>
<li>Global embolization and access product revenues grew to $95.4 million in the fourth quarter of 2024, an increase of 1.6%, or 1.5% in constant currency</li>
<li>U.S. embolization and access product revenue increased by 8.9%.</li>
<li>Operating income reached $42.8 million, with an adjusted&nbsp;operating income of $48.6 million&nbsp;in the fourth quarter of 2024.</li>
<li>Q4 net income reached $33.7 million, and adjusted EBITDA was $63.7 million, with margins of 10.7% and 19.8%, respectively.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42534137/penumbra-is-poised-to-gain-share-in-an-expanding-market-says-bullish-analyst" rel="noreferrer noopener">Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst</a>
<h2 class="wp-block-heading">Penumbra Guidance</h2>
The company forecasts fiscal year 2025 sales of $1.34 billion-$1.36 billion versus a consensus of $1.36 billion.
Penumbra projects the U.S. thrombectomy franchise will grow 19% to 20% year over year, driven primarily by its computer-assisted vacuum thrombectomy products.
The company also expects gross margin expansion of at least 100 basis points in 2025, to more than 67% for the full year, and operating margin expansion to 13% to 14% of revenue for 2025.
Analyst reactions:
<ul>
<li>Baird maintains the Outperform rating on Penumbra, raising the price target <a href="https://www.benzinga.com/quote/PEN/analyst-ratings" target="_blank" rel="noreferrer noopener">from $305 to $328</a>.</li>
<li>Needham reiterates Penumbra&#8217;s Hold rating.</li>
<li>Morgan Stanley maintains Penumbra with an Equal-Weight, raising the price target from $240 to $260.</li>
<li>Piper Sandler reiterates Penumbra with an Overweight, increasing the price target from $250 to $330.</li>
<li>Wells Fargo also reaffirms Penumbra&#8217;s Overweight rating, with a price target of $305, up from $275.</li>
<li>UBS analyst maintains Penumbra with a Buy and raises the price target from $305 to $320.</li>
<li>Canaccord Genuity maintains the Buy rating on Penumbra and raises the price target from $323 to $340.</li>
<li>Truist Securities reaffirms the Buy rating for Penumbra and raises the price target from $285 to $325.</li>
<li>RBC Capital maintains Penumbra with an Outperform rating and raises the price target from $285 to $313.</li>
<li>JP Morgan maintains Penumbra with an Overweight rating and raises the price target from $230 to $285.</li>
</ul>
Price Action: Penumbra stock is up 11.3% at $301.89 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43815436/supernus-pharmaceuticals-stock-falls-on-disappointing-data-from-treatment-resistant-depression-trial" target="_blank" rel="noreferrer noopener">Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial</a></li>
</ul>
Image: Shutterstock

Health Care

General

Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook

WIIM

VMAR

Vision Marine Technologies shares are trading higher after the company announced an enhanced collaboration with Electrified Marina.

Press Releases

Perdoceo Education Corporation Schedules Second Quarter Earnings Conference Call for July 31st

Perdoceo Education Corporation Reports Second Quarter and Year to Date 2024 Results

Short Sellers

Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Zebra Technologies Corp. (NASDAQ: ZBRA)

Perdoceo Education Corporation Schedules Third Quarter Earnings Conference Call for November 12th

Perdoceo Education Corporation Reports Third Quarter and Year to Date 2024 Results

Perdoceo Education Corporation completes its previously announced acquisition of University of St. Augustine for Health Sciences, LLC

Perdoceo Education Corporation Announces Quarterly Dividend

Perdoceo Education Corporation Schedules Fourth Quarter Earnings Conference Call for February 18th

Hanna Skandera Joins Perdoceo Education Corporation Board of Directors

Perdoceo Education Corporation Reports Fourth Quarter and Full Year 2024 Results

ZBRA

Afya

American Public Education, Inc. - Common Stock

American Public Education

Adtalem Global Education Inc. Common Stock

Adtalem Glb Education

Bright Horizons Family Solutions Inc. Common Stock

Bright Horizons Family

Chegg

Coursera

Youdao, Inc. American Depositary Shares, each representing one Class A Ordinary Share

Youdao

Duolingo

New Oriental Education & Technology Group, Inc. Sponsored ADR representing 10 Ordinary Share (Cayman Islands)

Comments

Perdoceo Education

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga